--- schema_version: "secwatch.filing_event.v1" accession: "0001437749-23-016196" form_type: "8-K" ticker: null cik: "0001029125" company_name: "Panbela Therapeutics, Inc." filed_at: "2023-05-31T23:59:59+00:00" generated_at: "2026-06-14T10:08:59.230860+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.65 calibrated_materiality_score: 0.65 confidence: "high" source: SEC EDGAR --- # Panbela Therapeutics implements 1-for-30 reverse stock split effective June 1, 2023 to regain Nasdaq compliance ## Summary - Reverse split at 1:30 ratio reduces outstanding shares from ~16.8M to ~559,560; effective June 1, 2023. - Split intended to increase per-share price to regain compliance with Nasdaq continued listing requirements. - Certificate of Elimination filed to cancel sole outstanding Series A Preferred Stock share, as approved by stockholders. - Stockholders ratified Cherry Bekaert as independent auditor and re-elected three Class I directors at May 25 annual meeting. - No fractional shares issued; holders of fractional shares to receive cash in lieu. ## SEC filing metadata - accession: 0001437749-23-016196 - form_type: 8-K - cik: 0001029125 - company_name: Panbela Therapeutics, Inc. - filed_at: 2023-05-31T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.65 - calibrated_materiality_score: 0.65 - confidence: high - sec_items: 3.03, 5.03, 5.07, 7.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/0001437749-23-016196-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/pbla20230530_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001437749-23-016196 - JSON: https://secwatch.observer/filing/0001437749-23-016196.json - Plain text: https://secwatch.observer/filing/0001437749-23-016196.txt ## Key facts - Governance Changes Panbela Therapeutics, Inc.: Filed Certificate of Amendment to effect 1-for-30 reverse stock split of common stock (effective 2023-06-01). - Change: charter amendment - Effective: 2023-06-01 source text: Accordingly, on May 30, 2023, the Company filed a Certificate of Amendment to the Restated Certificate of Incorporation (the “Amendment”) to effect the Reverse Split as of 12:01 a.m., eastern time, on June 1, 2023. evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/0001437749-23-016196-index.htm - Shareholder Votes Panbela Therapeutics, Inc. shareholders approved Approve one or more adjournments of the annual meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve proposal 4 at the 2023-05-25 meeting. - Outcome: passed - Meeting: 2023-05-25 source text: Proposal 5 – Approve one or more adjournments of the annual meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve proposal 4 Stockholders approved the adjournment of the annual meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 3, based on the votes listed below: For Against Abstain Broker Non-Votes 1,337,118 1,201,794 372,132 4,047,370 evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/0001437749-23-016196-index.htm - Shareholder Votes Panbela Therapeutics, Inc. shareholders approved Approve, on an advisory basis, the compensation of our named executive officers at the 2023-05-25 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-05-25 source text: Proposal 3 – Approve, on an advisory basis, the compensation of our named executive officers Stockholders approved, on an advisory basis, the compensation of our named executive officers, based on the votes listed below: For Against Abstain Broker Non-Votes 1,726,832 1,086,343 97,869 4,047,370 evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/0001437749-23-016196-index.htm - Shareholder Votes Panbela Therapeutics, Inc. shareholders approved Approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock, par value of $0.001 per share, at a reverse stock split ratio ranging from any whole number between 1-for-5 and 1-for-100, subject to and as determined by ou at the 2023-05-25 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2023-05-25 source text: Proposal 4 – Approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock, par value of $0.001per share, at a reverse stock split ratio ranging from any whole number between 1-for-5 and 1-for-100, subject to and as determined by our Board of Directors Stockholders approved the proposal, based on the votes listed below: For Against Abstain 65,416,517 41,528,948 12,947 evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/0001437749-23-016196-index.htm - Shareholder Votes Panbela Therapeutics, Inc. shareholders approved Election of Three Class I Directors at the 2023-05-25 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-05-25 source text: Proposal 1 – Election of Three Class I Directors Stockholders elected each of the three nominees to serve as a director for a three-year term ending at the annual meeting of stockholders to be held in 2026, based on the votes listed below: Director Nominee For Withhold Broker Non-Votes Daniel J. Donovan 2,147,152 763,892 4,047,370 Jeffrey E. Jacob 2,029,133 881,911 4,047,370 Jennifer K. Simpson 1,906,200 1,004,844 4,047,370 evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/0001437749-23-016196-index.htm - Shareholder Votes Panbela Therapeutics, Inc. shareholders approved Ratify the Selection of Independent Registered Public Accounting Firm at the 2023-05-25 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-05-25 source text: Proposal 2 – Ratify the Selection of Independent Registered Public Accounting Firm Stockholders ratified the selection of Cherry Bekaert LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 202, based on the votes listed below: For Against Abstain 5,688,661 1,153,686 116,067 evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923016196/0001437749-23-016196-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.